Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two presentations on sovateltide as a treatment for acute ischemic stroke at the 14th World Stroke Congress October 26-29, 2022, in Singapore.

Details for the presentations are as follows:

Title: A Randomized Multicenter Study to Determine The Efficacy of Sovateltide (Tycamzzi™) in Patients With Cerebral Ischemic Stroke
Presentation: Oral Presentation, #1714
Authors: A. Gulati (presenter), S. Adwani, V. Pamidimukkala, N. Agrawal, T. Ramakrishnan, H. Rai, D. Jain, N.Sundarachary, J. Pandian, V. Sardana, M. Sharma, G. Sidhu, S. Anand, D. Vibha, S. Aralikatte, D. Khurana, D. Joshi, U. Karadan, M. Imam
Session: 1200 – Free Communications 18: Clinical Trials I
Time/Date: 11:30 a.m. – 1 p.m. GMT+8, Saturday, October 29, 2022 (Singapore) / 11:30 p.m. – 1 a.m. EDT, Friday, October 28, 2022 (U.S.)
   
Title: Sovateltide (Tycamzzi™) Induces Neuronal Regeneration in The Adult Mammalian Cerebral Ischemic Brain By Stimulating Endothelin B Receptors
Presentation: E-Poster Presentation, #1763
Authors: A. Gulati (presenter), A. Ranjan, S. Briyal
Session: 0150 – Short Communications 02: Etiology and Clinical Presentations 02
Time/Date: 10 – 11:30 a.m. GMT+8, Wednesday, October 26, 2022 (Singapore) / 10 – 11:30 p.m. EDT, Tuesday, October 25, 2022 (U.S.)

About Pharmazz, Inc. 
Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional information may be found on the Company’s website, www.pharmazz.com.  

Media contacts:
Katie Larch / Robert Flamm, Ph.D.
Burns McClellan, Inc.
Email: klarch@burnsmc.com / rflamm@burnsmc.com

Investor contacts:
Eric Ando
Burns McClellan, Inc.
Email: eando@burnsmc.com

Shruti Gulati
Pharmazz Inc.
Email: shruti.gulati@pharmazz.com 
Phone: (630) 780-6087

 

Staff

Recent Posts

Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results

MILPITAS, Calif., March 26, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:…

54 minutes ago

CytoSite Bio Announces Agreement with Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment

A global collaboration agreement has been signed for the development and commercialization of a Granzyme…

54 minutes ago

MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

MARPAI EXHIBITS STRONG, ONGOING FINANCIAL IMPROVEMENT TAMPA, Fla., March 26, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai"…

54 minutes ago

SS&C Technologies Welcomes Seasoned Global Business Leader Francesco Vanni d’Archirafi to its Board of Directors

WINDSOR, Conn., March 26, 2025 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the election…

54 minutes ago

Chan Zuckerberg Initiative Announces New Biohub to Develop Breakthrough Imaging Technologies to Observe Cells in Action

The CZ Biohub San Francisco and CZ Imaging Institute will join together to develop novel…

54 minutes ago